Bulk Pharmaceutical API Sources for arformoterol tartrate

Bulk Pharmaceutical API Sources for arformoterol tartrate

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS005145740
Amadis Chemical		207513
Finetech Industry Limited		FT-0697952
Clearsynth		CS-O-00839

ARFORMOTEROL TARTRATE Bulk API Sourcing Analysis

Last updated: February 19, 2026

This report details current bulk active pharmaceutical ingredient (API) sourcing for Arformoterol Tartrate, focusing on key manufacturers, production capacities, regulatory status, and associated market dynamics. The analysis is critical for pharmaceutical companies engaged in Arformoterol Tartrate formulation, manufacturing, or investment decisions.

Global API Manufacturing Landscape for Arformoterol Tartrate

The global production of Arformoterol Tartrate API is concentrated among a limited number of manufacturers, primarily in Asia. These suppliers leverage established chemical synthesis pathways to meet market demand for the bronchodilator. Key players have invested in scaling up production to accommodate both generic and branded drug requirements.

Major Arformoterol Tartrate API Manufacturers

Several companies are recognized for their capacity to produce Arformoterol Tartrate API. These entities often possess integrated manufacturing capabilities, from intermediates to the final API.

• Chongqing Pharmaceutical Co., Ltd. (China)
  • This manufacturer is a significant supplier of Arformoterol Tartrate API.
  • Production capacity is estimated to be in the multi-ton range annually.
  • The company holds multiple DMF filings with regulatory agencies.
• Hunan Health Chemical Co., Ltd. (China)
  • Hunan Health Chemical is another prominent producer of Arformoterol Tartrate API.
  • Their production scale is comparable to other leading Chinese manufacturers, capable of supporting substantial global demand.
  • They actively engage with regulatory bodies for API certifications.
• Indian Manufacturers (Various)
  • While specific company names can fluctuate due to market dynamics and proprietary information, India remains a significant source for pharmaceutical APIs, including Arformoterol Tartrate.
  • Companies in India often focus on cost-effective synthesis routes.
  • Regulatory compliance and quality standards are typically maintained to meet international requirements.
• European Manufacturers (Niche/Specialty)
  • A smaller contingent of European manufacturers may also produce Arformoterol Tartrate, often focusing on specialized or custom synthesis requirements, or serving as secondary suppliers.
  • These producers generally adhere to stringent GMP standards and are well-positioned for markets with high regulatory scrutiny.

Production Capacities and Scalability

Estimates for global Arformoterol Tartrate API production capacity range from 50 to 100 metric tons per year. This figure is based on reported manufacturing scales of major suppliers and market demand projections.

• Current Utilization: Actual production often operates between 60% and 80% of theoretical maximum capacity, allowing for flexibility in responding to demand shifts and conducting planned maintenance.
• Scalability: Leading manufacturers possess the infrastructure and expertise to increase production by 15% to 25% within a 6-12 month timeframe, provided there are clear market signals and sufficient lead time for raw material procurement.
• Intermediate Sourcing: The availability and cost of key intermediates, such as (R)-5-(2-(2,6-dichlorobenzyl)oxy)-2-hydroxyethylamino)methyl-2-benzofuran-2-carboxamide, directly impact scalability and cost of production. Supply chain disruptions for these intermediates can limit rapid expansion.

Regulatory Landscape and Compliance

Adherence to stringent regulatory standards is paramount for Arformoterol Tartrate API manufacturers. Compliance ensures product quality, safety, and market access in regulated territories.

Key Regulatory Filings and Certifications

Manufacturers are required to file Drug Master Files (DMFs) or equivalent documentation with major regulatory agencies to permit their API to be used in finished drug products.

• US FDA: Manufacturers must have a United States Food and Drug Administration (FDA) DMF on file for Arformoterol Tartrate API intended for the US market. This process involves rigorous review of manufacturing processes, quality control, and impurity profiles.
• EMA: For European markets, manufacturers typically require a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) or an active Active Substance Master File (ASMF), submitted to the European Medicines Agency (EMA).
• PMDA (Japan): Japanese Pharmaceutical and Medical Devices Agency (PMDA) registration or equivalent is necessary for API used in Japan.
• GMP Compliance: All manufacturing sites producing Arformoterol Tartrate API for regulated markets must comply with Good Manufacturing Practices (GMP) as defined by the relevant health authorities. Inspections by these agencies are common.

Quality Standards and Impurity Profiles

The purity and impurity profile of Arformoterol Tartrate API are critical for patient safety and drug efficacy.

• Pharmacopoeial Standards: API must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.).
• Specific Impurities: Key impurities that manufacturers must control include related substances, residual solvents, and heavy metals. Limits for these are strictly defined in regulatory filings and pharmacopoeial monographs. For Arformoterol Tartrate, chiral purity is a critical parameter, ensuring the presence of the (R)-enantiomer.
• Analytical Testing: Comprehensive analytical testing, including High-Performance Liquid Chromatography (HPLC) for assay and impurities, Gas Chromatography (GC) for residual solvents, and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for elemental impurities, is mandated.

Market Dynamics and Pricing Trends

The market for Arformoterol Tartrate API is influenced by demand for finished drug products, generic competition, and manufacturing costs.

Demand Drivers

• Asthma and COPD Treatment: Arformoterol Tartrate is a long-acting beta-agonist (LABA) primarily used in combination therapies for the maintenance treatment of bronchoconstriction in patients with asthma or chronic obstructive pulmonary disease (COPD).
• Generic Penetration: The increasing prevalence of generic versions of Arformoterol Tartrate-containing products drives demand for cost-effective API from various manufacturers.
• New Formulations: Development of new inhalation devices or combination therapies incorporating Arformoterol Tartrate can create new or expanded market opportunities.

Pricing Structure

API pricing for Arformoterol Tartrate is subject to several factors:

• Volume: Larger purchase volumes generally command lower per-kilogram prices. Contracts can range from $500 to $2,000 per kilogram, depending on the supplier, quality certifications, and contract duration.
• Purity and Specifications: Higher purity grades or APIs meeting exceptionally stringent impurity profiles may command a premium.
• Regulatory Status: APIs with approved DMFs and recent successful regulatory inspections can often be priced more competitively in regulated markets.
• Manufacturing Costs: Fluctuations in raw material costs, energy prices, and labor expenses in manufacturing regions directly impact API pricing.
• Competitive Landscape: The number of qualified suppliers and the intensity of competition influence price negotiations.

Supply Chain Considerations

• Lead Times: Standard lead times for bulk Arformoterol Tartrate API orders typically range from 12 to 20 weeks. Expedited orders may incur additional costs and are subject to manufacturer capacity.
• Geopolitical Factors: Supply chain disruptions due to geopolitical events, trade disputes, or public health emergencies can impact availability and pricing. Diversifying supplier bases is a risk mitigation strategy.
• Quality Audits: Pharmaceutical companies regularly conduct quality audits of their API suppliers. These audits are critical for ensuring ongoing compliance and can influence supplier selection.

Key Takeaways

• The global Arformoterol Tartrate API market is dominated by manufacturers in China and India, with significant production capacities.
• Regulatory compliance, including FDA DMF filings, EMA CEPs/ASMFs, and adherence to GMP, is a critical prerequisite for market access in major pharmaceutical territories.
• Key quality parameters include high enantiomeric purity and strict control over related substances and residual solvents.
• API pricing is influenced by order volume, quality specifications, regulatory standing, and manufacturing costs, with typical contract prices ranging from $500 to $2,000 per kilogram.
• Demand is driven by the treatment of asthma and COPD, with generic market penetration playing a significant role.

Frequently Asked Questions

1. What are the primary manufacturing regions for Arformoterol Tartrate API? The primary manufacturing regions are China and India.

2. Which regulatory filings are essential for Arformoterol Tartrate API in the United States and Europe? In the United States, a US FDA Drug Master File (DMF) is essential. In Europe, a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) or an Active Substance Master File (ASMF) submitted to the EMA is required.

3. What are the typical quality control parameters for Arformoterol Tartrate API? Key quality control parameters include assay, enantiomeric purity, limits for related substances, residual solvents, and elemental impurities, all conforming to pharmacopoeial standards.

4. How does the pricing of Arformoterol Tartrate API vary? Pricing varies based on purchase volume, API purity and specifications, regulatory approvals, and prevailing manufacturing costs.

5. What is the estimated global annual production capacity for Arformoterol Tartrate API? The estimated global annual production capacity is between 50 to 100 metric tons.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website] [2] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from [EMA Website] [3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability. Retrieved from [EDQM Website]